Translating Evidence-Based Research into Value-Based Decisions in Oncology

Published Online: Tuesday, November 20, 2012
Follow Pharmacy_Times:
At a meeting hosted by the American Journal of Managed Care, key figures in the managed care industry discussed innovative payment models being utilized by payers and providers.
On Friday, November 16, 2012, the American Journal of Managed Care hosted its first annual live meeting, “Translating Evidence-Based Research into Value-Based Decisions in Oncology.” The meeting, which brought together stakeholders from all sides of the managed care industry, provided an arena for health care professionals to discuss new, innovative payment models being utilized by both payers and providers.
 
To view highlights from the meeting, click here.

Related Articles
Olaparib treats women with advanced ovarian cancer associated with defective BRCA genes.
Priced at approximately $178,000 for 2 courses of treatment, Blincyto will be one of the most expensive cancer medications on the market.
The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer.
Merck’s anti–PD-1 therapy Keytruda has demonstrated an overall response rate of 18.5% among patients with PD-L1 positive, advanced triple-negative breast cancer, one of the most aggressive forms of breast cancer.
Latest Issues
$auto_registration$